Otsuka Novel Products GmbH

Tweet this page
<
2015
2016
2017
2018
2019
2020
2022
2023
>
Registration as it was on 03 Nov 2023
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

300,000€ - 399,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

1.5 Fte (6)

Lobbyists with EP accreditation

0

High-level Commission meetings

1

Lobbying Costs over the years

  • Info

    Otsuka Novel Products GmbH   (ONPG)

    EU Transparency Register

    260256215861-19 First registered on 02 Feb 2015

    Goals / Remit

    Otsuka Novel Products GmbH (ONPG), based in Munich, Germany, was founded by the global Otsuka-group in 2011. The main focus of the company is the therapeutic area of tuberculosis.

    Main EU files targeted

    - Commission's Communication on a One-Health Action Plan to support Member States in the fight against Antimicrobial Resistance (AMR)

    - Agenda 2030 for Sustainable Development

    - Tuberculosis Action Plan for the WHO European Region 2023-2030

    Address

    Head Office
    Erika-Mann-Str. 21
    München 80636
    GERMANY
    EU Office
    Erika-Mann-Str. 21
    München 80636
    GERMANY

    Website

    http://otsuka-onpg.com

  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    25%6

    Lobbyists (Full time equivalent)

    1.5

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    https://www.eu-pearl.eu/
    https://www.amrindustryalliance.org/
    https://www.unite4tb.org/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    300,000€ - 399,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    300,000€ - 399,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    It is Otsuka Novel Products GmbH goal to increase awareness of Global tuberculosis pandemic, to improve access to diagnostic und medicines, rapid and equitable access to pharmaceuticals worldwide. Therefore, Otsuka is working with industry partners, governments, NGOs, health agencies in tuberculosis high burden countries.

    1. Otsuka is member of EU Patient-Centric Clinical Trial Platforms EU PEARL - https://www.eu-pearl.eu/

    This project is funded by the Innovative Medicines Initiative (IMI), a large, far-reaching public-private partnership integrated by the European Union and the pharmaceutical industry to support research and innovation in life-science.
    EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a tested and trusted framework for patient-centric integrated research platform (IRP) trials, through which novel techniques and treatments developed by multiple companies and organizations are tested in a platform trial.

    2. Otsuka is member of the Antimicrobial Resistance initiative (AMR) - https://www.amrindustryalliance.org/

    The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces. Antimicrobial resistance poses a formidable threat to the attainment of the Sustainable Development Goals (SDGs). The United Nations called in 2016 for concerted action from governments and various sectors to address the implications of antimicrobial resistance in a comprehensive manner, and implement strategies at national level.
    The AMR Industry Alliance is the life-sciences industry response to the call for action.

    Other activities

    Otsuka is member of the Innovative Medicines Initiative (IMI).

  • Meetings

    Meetings

    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    • Date 04 Feb 2015 Location Brussels,Belgium
      Subject EU health policy
      DG Günther Oettinger
      Attending
      • Günther Oettinger (Commissioner)
Download this datacard